Molecular serum markers of liver fibrosis

Biomarker Insights

Volumn 7, Issue , 2012, Pages 105-117

  Liu, Tianhui ^a,b   Wang, Xiaoming ^a,b   Karsdal, Morten A ^b   Leeming, Diana J ^b   Genovese, Federica ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Extracellular matrix; Liver fibrosis; Neo epitope; Serum marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 6; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLYCOPROTEIN; HYALURONIC ACID; INTERLEUKIN 6; LAMININ; MICROFIBRILLAR ASSOCIATED PROTEIN 4; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEOGLYCAN; SCLEROPROTEIN; SOMATOMEDIN; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNDULIN; YKL 40 PROTEIN;

AREA UNDER THE CURVE; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE MODEL; EXTRACELLULAR MATRIX; FIBROGENESIS; GOLD STANDARD; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MEDICAL ASSESSMENT; NON INVASIVE MEASUREMENT; NONHUMAN; PATIENT MONITORING; PROGNOSIS; PROTEIN PROCESSING; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; REVIEW; RISK ASSESSMENT; SAMPLING ERROR; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

RATTUS;

EID: 84864619707     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S10009     Document Type: Review

References (127)

1. BatallerR, BrennerDA. Liverfibrosis. J Clin Invest. Feb2005;115(2):209-18.
2. BrundtlandGH. FromtheWorldHealthOrganization. Reducingriskstohealth, promotinghealthylife. JAMA. Oct23,2002;288(16):1974.
3. FriedmanSL. Molecularregulationofhepaticfibrosis, anintegratedcellular responsetotissueinjury. J Biol Chem. Jan28,2000;275(4):2247-50.
4. FriedmanSL. Mechanismsofhepaticfibrogenesis. Gastroenterology. May2008;134(6):1655-69.
5. FriedmanSL. Liverfibrosis-frombenchtobedside. J Hepatol.2003;38Suppl1:S38-53.
6. AhmadW, IjazB, GullS, etal. Abriefreviewonmolecular, geneticandimagingtechniquesforHCVfibrosisevaluation. Virol J.2011;8(1):53.
7. SebastianiG, AlbertiA. Noninvasivefibrosisbiomarkersreducebutnotsubstitutetheneedforliverbiopsy. World J Gastroenterol. Jun21,2006;12(23):3682-94.
8. RossiE, AdamsLA, BulsaraM, JeffreyGP. Assessingliverfibrosiswithserum marker models. Clin Biochem Rev. Feb2007;28(1):3-10.
9. ZhouK, LuLG. Assessmentoffibrosisinchronicliverdiseases. J Dig Dis. Feb2009;10(1):7-14.
10. GrigorescuM. Noninvasivebiochemicalmarkersofliverfibrosis. J Gastrointestin Liver Dis. Jun2006;15(2):149-59.
11. GressnerOA, WeiskirchenR, GressnerAM. Biomarkersofhepaticfibrosis, fibrogenesisandgeneticpre-dispositionpendingbetweenfictionandreality. J Cell Mol Med. Sep2007;11(5):1031-51.
12. VeidalSS, Bay-JensenAC, TougasG, KarsdalMA, VainerB. Serummarkersofliverfibrosis:combiningtheBIPEDclassificationandtheneo-epitopeapproachinthedevelopmentofnewbiomarkers. Dis Markers. 2010;28(1):15-28.
13. FeldsteinAE, CanbayA, AnguloP, etal. Hepatocyteapoptosisandfasexpressionareprominentfeaturesofhumannonalcoholicsteatohepatitis. Gastroenterology. Aug2003;125(2):437-43.
14. KohliV, SelznerM, MaddenJF, BentleyRC, ClavienPA. Endothelialcellandhepatocytedeathsoccurbyapoptosisafterischemia-reperfusioninjuryin the rat liver. Transplantation. Apr27,1999;67(8):1099-105.
15. NatoriS, SelznerM, ValentinoKL, etal. Apoptosisofsinusoidalendothelialcellsoccursduringliverpreservationinjurybyacaspase-dependentmechanism. Transplantation. Jul15,1999;68(1):89-96.
16. NatoriS, RustC, StadheimLM, SrinivasanA, BurgartLJ, GoresGJ. Hepatocyteapoptosisisapathologicfeatureofhumanalcoholichepatitis. J Hepatol. Feb2001;34(2):248-53.
17. NatoriS, HiguchiH, ContrerasP, GoresGJ. ThecaspaseinhibitorIDN-6556preventscaspaseactivationandapoptosisinsinusoidalendothelialcellsduringliverpreservationinjury. Liver Transpl. Mar2003;9(3):278-84.
18. PapakyriakouP, TzardiM, ValatasV, etal. Apoptosisandapoptosisrelatedproteinsinchronicviralliverdisease. Apoptosis. Apr2002;7(2):133-41.
19. RibeiroPS, Cortez-PintoH, SolaS, etal. Hepatocyteapoptosis, expressionofdeathreceptors, andactivationofNF-kappaBintheliverofnonalcoholicandalcoholicsteatohepatitispatients. Am J Gastroenterol. Sep2004;99(9):1708-17.
20. FriedmanSL. Mechanismsofdisease:Mechanismsofhepaticfibrosisandtherapeuticimplications. Nat Clin Pract Gastroenterol Hepatol. Dec2004;1(2):98-105.
21. TomasekJJ, GabbianiG, HinzB, ChaponnierC, BrownRA. Myofibroblastsandmechano-regulationofconnectivetissueremodelling. Nat Rev Mol Cell Biol. May2002;3(5):349-63.
22. WynnTA. Commonanduniquemechanismsregulatefibrosisinvariousfibroproliferativediseases. J Clin Invest. Mar2007;117(3):524-9.
23. WynnTA. Cellularandmolecularmechanismsoffibrosis. J Pathol. Jan2008;214(2):199-210.
24. SchuppanD, RuehlM, SomasundaramR, HahnEG. Matrixasamodulatorofhepaticfibrogenesis. Semin Liver Dis. Aug2001;21(3):351-72.
25. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis. 1999;19(2): 129-40.
26. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. Aug 2001;21(3):397-416.
27. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. Aug 2000;279(2):G245-9.
28. Arthur MJ, Stanley A, Iredale JP, Rafferty JA, Hembry RM, Friedman SL. Secretion of 72kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem J. Nov 1, 1992;287(Pt 3):701-7.
29. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc. 2009;120:361-8.
30. Han YP, Yan C, Zhou L, Qin L, Tsukamoto H. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem. Apr 27, 2007; 282(17):12928-39.
31. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). Feb 2008;233(2):109-22.
32. Vyas SK, Leyland H, Gentry J, Arthur MJ. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology. Sep 1995;109(3):889-98.
33. Daxboeck F, Gattringer R, Mustafa S, Bauer C, Assadian O. Elevated serum alanine aminotransferase (ALT) levels in patients with serologically verified Mycoplasma pneumoniae pneumonia. Clin Microbiol Infect. Jun 2005;11(6):507-10.
34. Akkaya O, Kiyici M, Yilmaz Y, Ulukaya E, Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol. Nov 7, 2007;13(41):5481-5.
35. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. Dec 2000;46(12):2027-49.
36. Sherman KE. Alanine aminotransferase in clinical practice. A review. Arch Intern Med. Feb 1991;151(2):260-5.
37. Shiffman ML, Diago M, Tran A, etal. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol. May 2006;4(5):645-52.
38. Zechini B, Pasquazzi C, Aceti A. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol. Sep 2004;16(9):891-6.
39. Giannini E, Risso D, Botta F, etal. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. Jan 27, 2003;163(2):218-24.
40. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. Jan 1998;93(1):44-8.
41. Fujii H, Enomoto M, Fukushima W, et al. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol. 2009;44(6):608-14.
42. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. Jun 2005;41(6):1376-82.
43. Reedy DW, Loo AT, Levine RA. AST/ALT ratio. or= 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci. Sep 1998; 43(9):2156-9.
44. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut. Apr 2000; 46(4):443-6.
45. Gelse K, Poschl E, Aigner T. Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev. Nov 28, 2003;55(12):1531-46.
46. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol. Aug 2003;39(2):179-86.
47. Rosenberg WM, Voelker M, Thiel R, etal. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. Dec 2004; 127(6):1704-13.
48. Teare JP, Sherman D, Greenfield SM, etal. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet. Oct 9, 1993;342(8876):895-8.
49. Collazos J, Diaz F. Role of the measurement of serum procollagen type III N-terminal peptide in the evaluation of liver diseases. Clin Chim Acta. Jun 1994;227(1-2):37-43.
50. Gabrielli GB, Capra F, Casaril M, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta. Sep 8, 1997;265(1):21-31.
51. Giannini E, Caglieris S, Ceppa P, Risso D, Lantieri PB, Testa R. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. Feb 2001; 13(2):137-41.
52. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem. Apr 1996; 42(4):558-63.
53. Montalto G, Soresi M, Aragona F, et al. Procollagen III and laminin in chronic viral hepatopathies. Presse Med. Jan 20, 1996;25(2):59-62.
54. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. Jun 2007;381(2):107-13.
55. Hiwatari N, Shimura S, Yamauchi K, Nara M, Hida W, Shirato K. Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients. Tohoku J Exp Med. Feb 1997;181(2):285-95.
56. Lohr M, Hummel F, Martus P, etal. Serum levels of extracellular matrix in acute pancreatitis. Hepatogastroenterology. Nov 1999;46(30): 3263-70.
57. Tebib JG, Viguier P, Noel E, Colson F, Barbier Y, Bouvier M. Serum N terminal procollagen III fragment: a predictive marker of joint destruction in rheumatoid arthritis? Clin Rheumatol. Dec 1992;11(4):502-7.
58. Gabrielli GB, Corrocher R. Hepatic fibrosis and its serum markers: a review. Dig Dis. 1991;9(5):303-16.
59. Maruyama K, Okazaki I, Takagi T, Ishii H. Formation and degradation of basement membrane collagen. Alcohol Alcohol Suppl. 1991;1:369-74.
60. Hirayama C, Suzuki H, Takada A, Fujisawa K, Tanikawa K, Igarashi S. Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide. J Gastroenterol. Apr 1996;31(2):242-8.
61. Leeming DJ, Nielsen MJ, Dai Y, etal. Enzyme-linked immunosorbent serum assay specific for the 7S domain of Collagen Type IV (P4NP 7S): A marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res. Jan 5, 2012.
62. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair. 2010;3(1):5.
63. Schytte S, Hansen M, Moller S, et al. Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Scand J Clin Lab Invest. Dec 1999;59(8):627-33.
64. Vassiliadis E, Veidal SS, Simonsen H, etal. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers. Aug 2011; 16(5):426-33.
65. McGary CT, Raja RH, Weigel PH. Endocytosis of hyaluronic acid by rat liver endothelial cells. Evidence for receptor recycling. Biochem J. Feb 1, 1989;257(3):875-84.
66. McHutchison JG, Blatt LM, De Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol. Aug 2000;15(8):945-51.
67. Stickel F, Poeschl G, Schuppan D, et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol. Sep 2003;15(9):945-50.
68. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. May 1998;5(3):187-92.
69. Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol. May 28, 2009;15(20):2433-40.
70. Emlen W, Niebur J, Flanders G, Rutledge J. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity. J Rheumatol. Jun 1996;23(6):974-8.
71. Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med. Nov 2005; 258(5):460-6.
72. Tran A, Benzaken S, Saint-Paul MC, etal. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol. Sep 2000;12(9):989-93.
73. Berres ML, Papen S, Pauels K, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40serum levels in chronic hepatitis C infection. J Hepatol. Feb 2009;50(2):370-6.
74. Saitou Y, Shiraki K, Yamanaka Y, etal. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol. Jan 28, 2005;11(4):476-81.
75. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. May 2006;53(2):172-209.
76. Molleken C, Sitek B, Henkel C, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. Apr 2009;49(4):1257-66.
77. Leroy V, Monier F, Bottari S, etal. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. Feb 2004;99(2):271-9.
78. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem. Mar 29, 2002;277(13):11069-76.
79. Kerkvliet EH, Docherty AJ, Beertsen W, Everts V. Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. Matrix Biol. Aug 1999; 18(4):373-80.
80. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. Mar 1999;44(3):624-30.
81. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. Feb 2002;316(1-2):71-81.
82. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin Biochem. Jul 2010; 43(10-11):793-804.
83. Fosang AJ, Stanton H, Little CB, Atley LM. Neoepitopes as biomarkers of cartilage catabolism. Inflamm Res. Jun 2003;52(7):277-82.
84. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. May 2009;14(3):181-202.
85. Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. Jul 2010;43(10-11):899-904.
86. Segovia-Silvestre T, Reichenbach V, Fernandez-Varo G, etal. Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair. 2011;4:19.
87. Vassiliadis E, Larsen DV, Clausen RE, etal. Measurement of CO3-610, a Potential Liver Biomarker Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type III, in a Rat Model of Reversible Carbon-Tetrachloride-Induced Fibrosis. Biomark Insights. 2011;6:49-58.
88. Veidal SS, Karsdal MA, Nawrocki A, et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. 2011;4:22.
89. Veidal SS, Karsdal MA, Vassiliadis E, etal. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS One. 2011; 6(9):e24753.
90. Leeming D, He Y, Veidal S, etal. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. Nov 2011;16(7):616-28.
91. Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis. Nov 2008;12(4):825-52.
92. Kanzler S, Baumann M, Schirmacher P, etal. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat. Nov 2001;8(6):430-7.
93. Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1-possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology. Sep 2002; 49(47):1369-72.
94. Roth S, Michel K, Gressner AM. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology. Apr 1998;27(4):1003-12.
95. McClain C, Barve S, Joshi-Barve S, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res. Nov 2005; 29(Suppl 11):180S-8S.
96. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol. Jun 7, 2005; 11(21):3260-3.
97. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol. Jan 2006;44(1):57-66.
98. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. Aug 2004;15(4):255-73.
99. Zhang BB, Cai WM, Weng HL, et al. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol. Nov 2003;9(11):2490-6.
100. Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol. Nov 2007;47(5):699-710.
101. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. Sep 2008;28(8): 1065-79.
102. Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem. Sep 2006;52(9):1815-7.
103. Kovalenko E, Tacke F, Gressner OA, etal. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat. Sep 2009; 16(9):612-20.
104. Naiki M, Takagaki Y, Fujiwara K. Note on the change of transaminases in the liver and the significance of the transaminase ratio in experimental Tyzzer's disease of mice 1. Jpn J Exp Med. Aug 1965;35(4):305-9.
105. Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C 1. Am J Gastroenterol. Sep 2000;95(9):2328-32.
106. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. Apr 2000; 15(4):386-90.
107. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. Mar 15, 2005;71(6):1105-10.
108. Wai CT, Greenson JK, Fontana RJ, etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C 1. Hepatology. Aug 2003;38(2):518-26.
109. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review 5. Hepatology. Sep 2007;46(3): 912-21.
110. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis 1. Hepatology. Mar 2011;53(3):726-36.
111. Poynard T, Imbert-Bismut F, Munteanu M, etal. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. Sep 2004 23;3(1):8.
112. Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases 1. Hepatology. Feb 2006;43(2):373-4.
113. Myers RP, Benhamou Y, Imbert-Bismut F, etal. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients 4. AIDS. Mar 28, 2003;17(5):721-5.
114. Rossi E, Adams L, Prins A, etal. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients 1. Clin Chem. Mar 2003;49(3):450-4.
115. Varaut A, Fontaine H, Serpaggi J, etal. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus 1. Transplantation. Dec 15, 2005;80(11):1550-5.
116. Wilson LE, Torbenson M, Astemborski J, etal. Progression of liver fibrosis among injection drug users with chronic hepatitis C 1. Hepatology. Apr 2006;43(4):788-95.
117. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis 4. Hepatology. Feb 2006;43(2 Suppl 1):S113-20.
118. Cales P, Oberti F, Michalak S, etal. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. Dec 2005;42(6):1373-81.
119. Leroy V, Hilleret MN, Sturm N, etal. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. May 2007;46(5):775-82.
120. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis 1. BMC Gastroenterol. 2010;10:103.
121. Mayo MJ, Parkes J, ms-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay 1. Hepatology. Nov 2008;48(5):1549-57.
122. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. Jan 2009;136(1):160-7.
123. Stevenson M, Lloyd-Jones M, Morgan MY, Wong R. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technol Assess. Feb 2012;16(4):1-174.
124. Bauer DC, Hunter DJ, Abramson SB, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. Aug 2006; 14(8):723-7.
125. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. May 2008;134(6):1670-81.
126. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. Mar 8, 2008;371(9615): 838-51.
127. Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci. 2010;8:70.